Aspen to start J&J 19 vaccine supplies to South Africa from Monday



JOHANNESBURG, July 26 (Reuters) - South Africa's Aspen Pharmacare APNJ.J will supply the first batch of Johnson & Johnson JNJ.N COVID-19 vaccine to the country from July 26, the drugmaker said on Monday.

It will be the first set of vaccines to be manufactured in the country from active pharmaceutical ingredients (API) - substances used to make the final drug product - sourced from Europe, Aspen said.

South Africa's vaccination drive suffered a major setback in April after U.S. Federal Drug Administration halted production of J&J vaccines at a plant in Baltimore run by Emergent Biosolutions Inc EBS.N after it was found to be contaminated.

Aspen, which has been contracted by J&J to manufacture the vaccines in South Africa in a process called 'fill and finish', had been sourcing APIs from the Baltimore plant and was asked to destroy 2 million doses as part of the finding of the FDA.

The supplies will also be distributed to other African countries under the African Vaccine Acquisition Task Team under which J&J has committed to supply 220 million doses of the single shot vaccine, Aspen said.

Africa's dependence on imports of COVID-19 vaccine has left it vulnerable to repeated waves of the coronavirus, raising demands for vaccine production facilities in the continent.

It has administered just 60 million vaccine doses in a population of 1.3 billion due to restrictions on shipments from vaccine producing nations.

South Africa's Biovac Institute struck a deal with Pfizer PFE.N last week for a "fill and finish" arrangement to produce 100 million vaccines by 2022-23.

"Supply for Africa and South Africa is particularly rewarding, given the current global inequality in accessing vaccines," Stephen Saad, chief executive of Aspen said in a statement. "This represents a big step forward in ensuring that Africa can address its healthcare priorities."


Reporting by Promit Mukherjee Editing by Tomasz Janowski

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.